Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy

Clinical Reviews in Allergy and Immunology

Volumn 29, Issue 3, 2005, Pages 307-310

  Sapir, Tal ^a,b   Shoenfeld, Yehuda ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmunity; Cancer; Intravenous immunoglobulin; IVIg

Indexed keywords

DOXORUBICIN; GELATINASE B; I KAPPA B; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 12; MESSENGER RNA;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CELL ACTIVATION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; HUMAN; IMMUNE DEFICIENCY; KAPOSI SARCOMA; MELANOMA; METASTASIS INHIBITION; MULTIMODALITY CANCER THERAPY; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NERVE SHEATH TUMOR; NONHUMAN; PERIPHERAL NERVE; PLASMA; POLYMYOSITIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; THROMBOCYTOPENIC PURPURA; TUMOR CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; NEOPLASMS;

EID: 29944431959     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1385/CRIAI:29:3:307     Document Type: Article

References (25)

1. Fishman, P., Bar-Yehuda, S., and Shoenfeld, Y. (2002), Int J Oncol 21, 875-880.
2. Kazatchkine, M. D. and Kaveri, S. V. (2001), N Engl J Med 345, 747-755.
3. Marinos, C., Dalakas, M. C., and Spath, P. J. In: Marinos, C., Dalakas, M. C., Spath, P. J., eds. Intravenous Immunoglobulins in the Third Millennium. New York/London: Parthenon Publishing Group, 2004, pp. 1-409.
4. Segal, E. and Shoenfeld, Y. (2001), Harefuah 140, 955-958.
5. Dalakas, M. C. (1997), Ann Intern Med 126, 721-730.
6. Shoenfeld, Y. and Fishman, P. (1999), Int Immunol. 11, 1247-1252.
7. Tomer, Y. and Shoenfeld, Y. In: Shoenfeld, Y., Gershwin, E. M., eds. Cancer and Autoimmunity. Amsterdam: Elsevier, 2000, pp. 141-150.
8. Tishler, M. and Shoenfeld, Y. In: Shoenfeld, Y., Gershwin, E. M., eds. Cancer and Autoimmunity. Amsterdam: Elsevier, 2000, pp.121-132.
9. Sherer, Y. and Shoenfeld, Y. In: Shoenfeld, Y., Gershwin, E. M., eds. Cancer and Autoimmunity. Amsterdam: Elsevier, 2000, pp. 249-252.
10. Huminer, D., Tomer, Y., Pitlick, S., and Shoenfeld, Y. (1991), Autoimmunity 5, 232-233.
11. Swissa, M., Cohen, Y., and Shoenfeld, Y. (1990), Cancer 65, 2554-2558.
12. Shoenfeld, Y. and Isenberg, D. A. (1989), Immunol Today 10, 123-126.
13. Shoenfeld, Y., Kennedy, R., Ferrano, S., eds. (1997), Idiotypes in Autoimmunity, Infectious Diseases and Cancer. Amsterdam: Elsevier.
14. Shapiro, S., Shoenfeld, Y., Gilburd, B., Sobel, E., and Lahat, N. (2002), Cancer 95, 2032-2037.
15. Vassilev, T. L., Kazatchkine, M. D., Van Huyen, J. P., et al. (1999), Blood 93, 3624-3631.
16. Ichiyama, T., Ueno, Y., Isumi, H., Niimi, A., Matsubara, T., and Furukawa, S. (2004), Inflamm Res 53, 253-256.
17. Ekberg, C., Nordstrom, E., Skansen-Saphir, U., et al. (2001), Hum Immunol. 62, 215-227.
18. Besa, E. C. (1984), Am J Med 76, 209-218.
19. Carmeli, Y., Mevorach, D., Kaminski, N., Raz, E. (1994), Cancer 73, 2859-2861.
20. Shoenfeld, Y., Levy, Y., and Fishman, P. (2001), IMAJ 3, 698-699.
21. Merimsky, O., Meller, I., Inbar, M., Bar-Yehuda, S., Shoenfeld, Y., and Fishman, P. (2002), Int J Oncol. 20, 839-843.
22. Sipak-Szmigiel, O., Ronin-Walknowska, E., and Miklaszwicz, A. (2003), Ginekol Pol 74, 350-355.
23. US Patent no. 5,562,902. (1996), Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin.
24. US Patent no. 5,965,130. (1999), Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin.
25. Bar-Dayan, Y., Barshack, I., Blank, M., et al. (1999), Int J Oncol. 15, 1091-1096.